10.1038/nrd4233 61 KarlsederJ.BroccoliD.DaiY.HardyS.de LangeT
Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes
Comparative Mechanism Studies: Contrasting retatrutides effects with established GLP-1 agonists to identify novel therapeutic windows
However, these effects are often mild, and appear to dissipate over time with continuous use, with patients treated with liraglutide returning to near-baseline gastric emptying by week 8 of therapy
Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses
The columns (DAY 1, DAY 2, DAY 3, and DAY 4) represent the average values with the standard deviations